2022 American Transplant Congress
Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center
*Purpose: To compare rates of post-transplant lymphoproliferative disorder (PTLD) in patients treated with Belatacept and low-dose calcineurin inhibitors (CNIs) versus patients only treated with standard-dose…2022 American Transplant Congress
Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure Of Rituximab (R) ± Chemotherapy (CT) (ALLELE)
*Purpose: Tab-cel is an investigational, off-the-shelf, allogeneic EBV-specific T-cell immunotherapy for serious EBV-driven diseases, including EBV+ PTLD. Poor overall survival (OS) in patients (pts) with…2022 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…2022 American Transplant Congress
Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients with EBV DNAemia: A Case Series from the Pediatric Nephrology Research Consortium (PNRC)
*Purpose: The use of Rituximab (RTX) to prevent PTLD in patients with EBV DNAemia is an established strategy in hematopoietic stem cell transplants, but with…2022 American Transplant Congress
PTLD Suspected by Visualization of Atypical Urinary Lymphocytes
*Purpose: Urinalysis has been used for the detection of acute rejection but visualization of atypical lymphocytes in the urine sediment as an early sign of…2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…2021 American Transplant Congress
Gain of Function Mutations in Latent Membrane Protein 1 of Epstein Barr Virus are Associated with Increased Risk of Post-Transplant Lymphoproliferative Disorder
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is a prospective…2020 American Transplant Congress
Incidence of Skin Cancer – A Long Term Outcome of Immunosuppression in Renal Transplant Recipients Associated with the Usage of Azathioprine
*Purpose: The main cause of mortality in Kidney Transplant Recipient’s (KTRs) is malignancy. The cancer incidence is increased by treating with immunosuppressive agents and longer…
- 1
- 2
- 3
- …
- 9
- Next Page »